PURPOSE: We performed a phase I trial of @entity3003 and @entity1311 in combination with @entity136 in order to determine the tolerability of this triplet. METHODS: Enrolled in the study were 26 @entity1 with @entity5 , most with @entity1149 . The @entity1 received escalating doses of @entity3003 and @entity1311 on day 1 and @entity136 (30-min infusion) on days 1, 8, and 15 of a 28-day treatment cycle. The doses of each drug ranged from an area under the concentration-time curve (AUC) of 5 to 6 for @entity3003 , 135 to 175 mg/m(2) for @entity1311 , and 300 to 1000 mg/m(2) for @entity136 . RESULTS: @entity1503 was the most commonly observed @entity137 and was dose-limiting. During the first cycle at the recommended phase II dose, there were two instances of grade 4 @entity1398 and one instance of grade 4 @entity882 among six @entity1 , none of which was dose-limiting. Cumulative hematologic @entity137 emerged in subsequent cycles. @entity1503 were mild. Five @entity1 , all with previously untreated @entity1149 ( @entity1149 ), had a partial response. Nine @entity1 with @entity1149 or upper @entity344 experienced stable disease. CONCLUSIONS: Based on significant @entity1398 and @entity882 , the regimen recommended for further study consists of @entity3003 AUC 5, @entity1311 175 mg/m(2), and @entity136 1000 mg/m(2) on a 28-day cycle. The antitumor activity noted suggests that further investigation of this well-tolerated combination in specific @entity5 types, especially @entity1149 , is warranted.

Phase I combination trial of XXXX , @entity1311 , and @entity3003 in @entity1 with advanced @entity5 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'advanced cancer'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small-cell lung cancer', 'non-small cell lung cancer'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal malignancies'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['Non-hematologic toxicities', 'Hematologic toxicity'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']
@entity136 :: (MESH:C056507,Chemical) :: ['gemcitabine']
